BDTX News and Press, Black Diamond Therapeutics Inc.

2026-03-25 08:53:10 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

2026-03-16 17:00:32 ET More on Black Diamond Therapeutics Seeking Alpha’s Quant Rating on Black Diamond Therapeutics Historical earnings data for Black Diamond Therapeutics Financial information for Black Diamond Therapeutics Read the full article on...

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline setting Company is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR alter...

EHang Holdings Limited (EH) is expected to report $-0.06 for Q4 2025 McEwen Inc. (MUX) is expected to report $0.25 for Q4 2025 Hannover Ruck SE ADR - Level I (HVRRY) is expected to report $1.03 for Q4 2025 VAALCO Energy Inc. (EGY) is expected to report $0.02 for Q4 2025 Full Truck...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

2026-01-16 07:05:20 ET Kelsey Goodwin from Piper Sandler issued a price target of $8.00 for BDTX on 2026-01-16 11:54:48. The adjusted price target was set to $8.00. At the time of the announcement, BDTX was trading at $2.67. The overall price target consensus is at $8.00...

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to date PFS data for 1L NSCLC patients expected in Q2 2026; Co...

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, w...

2025-11-20 08:57:54 ET Top-line Summary and Update Read the full article on Seeking Alpha For further details see: Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor...